


Mulberroside A

Cat. No.:	HY-N0619		
CAS No.:	102841-42-9		
Molecular Formula:	C ₂₆ H ₃₂ O ₁₄		
Molecular Weight:	568.52		
Target:	TNF Receptor; Interleukin Related; Tyrosinase		
Pathway:	Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 100 mg/mL (175.90 mM)
 * "≥" means soluble, but saturation unknown.

	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	1.7590 mL	8.7948 mL	17.5895 mL
	5 mM	0.3518 mL	1.7590 mL	3.5179 mL
	10 mM	0.1759 mL	0.8795 mL	1.7590 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 0.5% CMC-Na/saline water
Solubility: 10 mg/mL (17.59 mM); Suspended solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.5 mg/mL (4.40 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (4.40 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (4.40 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Mulberroside A is one of the main bioactive constituent in mulberry (*Morus alba* L.)^[1]. Mulberroside A decreases the expressions of TNF-α, IL-1β, and IL-6 and inhibits the activation of NALP3, caspase-1, and NF-κB and the phosphorylation of ERK, JNK, and p38, exhibiting anti-inflammatory antiapoptotic effects^[2]. Mulberroside A shows inhibitory activity against mushroom tyrosinase with an IC₅₀ of 53.6 μM^[3].

IC ₅₀ & Target	IL-1 β	IL-6
In Vivo	Mulberroside A (10, 20, and 40 mg/kg) decreases serum uric acid levels and increases urinary urate excretion and fractional excretion of uric acid in hyperuricemic micem ^[4] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	Male Kun-Ming mice (20 \pm 2 g) ^[4]
	Dosage:	5, 10, 20, and 40 mg/kg; the dose volume 10 mL/kg body weight
	Administration:	Orally initiated at 9:00 a.m.
	Result:	10, 20, and 40 mg/kg significantly increased urinary urate excretion in 24 h, resulting in a remarkable elevation of fractional excretion of uric acid (FEUA), and the highest dose completely reversed FEUA alteration of hyperuricemic mice to normal.

CUSTOMER VALIDATION

- iScience. 2023 Jan 5;26(2):105936.
- Int Immunopharmacol. 2024 Jan 16;128:111537.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Mei M, et al. In vitro pharmacokinetic characterization of mulberroside A, the main polyhydroxylated stilbene in mulberry (*Morus alba* L.), and its bacterial metabolite oxysesveratrol in traditional oral use. *J Agric Food Chem*. 2012 Mar 7;60(9):2299-308.
- [2]. Wang CP, et al. Mulberroside A protects against ischemic impairment in primary culture of rat cortical neurons after oxygen-glucose deprivation followed by reperfusion. *J Neurosci Res*. 2014 Jul;92(7):944-54.
- [3]. Kim JK, et al. Biotransformation of mulberroside A from *Morus alba* results in enhancement of tyrosinase inhibition. *J Ind Microbiol Biotechnol*. 2010 Jun;37(6):631-7.
- [4]. Cai-Ping Wang, et al. Mulberroside a possesses potent uricosuric and nephroprotective effects in hyperuricemic mice. *Planta Med*. 2011 May;77(8):786-94.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA